Why the study?
To evaluate the efficacy and safety of finerenone compared to placebo in improving renal outcomes in patients with chronic kidney disease and type 2 diabetes.
Does finerenone reduce kidney failure and ESKD in adults with chronic kidney disease and type 2 diabetes?
Does finerenone reduce kidney failure and ESKD in adults with chronic kidney disease and type 2 diabetes?
In patients with CKD and T2D, finerenone's renal benefits remain uncertain due to wide confidence intervals, while it significantly increases the risk of hyperkalemia-related hospitalizations.
Answers are grounded in this paper and cite their sources.
Uncertainty persists on finerenone renal protection in CKD with T2D; challenges broad adoption given increased hyperkalemia hospitalizations.
Background/Objectives: To evaluate the efficacy and safety of finerenone compared to placebo in improving renal outcomes in patients with chronic kidney disease (CKD) and type 2 diabetes (T2D). Methods: A systematic review and meta-analysis were conducted, compiling RCTs evaluated the effect of finerenone compared to placebo in patients with CKD and T2D. Inclusion criteria included adults with CKD and T2D. Outcomes included kidney failure, end-stage renal disease (ESKD), and persistently decreased glomerular filtration rate (eGFR). Secondary outcomes included cardiovascular events, hospitalization due to hyperkalemia, and serious adverse events. Pooled relative risks (RRs) and mean differences (MDs) were calculated using a random-effects model. Results: Three RCTs with a total of 19,027 patients were included. Finerenone demonstrated a potential reduction in kidney failure risk (RR 0.86, 95% CI: 0.35–2.13) and ESKD (RR 0.82, 95% CI: 0.54–1.23); however, confidence intervals included the null effect. There were no statistically significant differences, as seen in the decrease in eGFR (RR 1.03; 95% CI: 0.27–3.85), but also in mortality due to renal causes (RR 0.62; 95% CI: 0.00–7168.81). Finerenone increased hyperkalemia-related hospitalizations (RR 4.57, 95% CI: 1.07–19.48) but had no significant effect on serious adverse events (RR 0.94, 95% CI: 0.92–0.97) or systolic BP (MD 0.08 mmHg, 95% CI: −0.36 to 0.52). Conclusions: Finerenone may provide renal protection in CKD and T2D, though benefits remain uncertain due to wide confidence intervals and study heterogeneity. The increased risk of hyperkalemia warrants careful patient selection and monitoring. Further research is needed to refine its clinical applicability. Review registration: PROSPERO CRD420250642593.
No takes yet. Share an insight, caveat, or question.
Díaz et al. (2025) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: